Correspondence 0001493152-25-005219 from FibroBiologics, Inc. (FBLG)

FibroBiologics, Inc.
Date: Feb. 6, 2025 · CIK: 0001958777 · Accession: 0001493152-25-005219

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-284663

Date

Feb. 6, 2025

Author

FibroBiologics

Form

CORRESP

Company

FibroBiologics, Inc.

Letter

VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Joshua Gorsky RE: FibroBiologics, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333- 284663

Dear Mr. Gorsky:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-284663) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on February 10, 2025, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.

We request that we be notified of such effectiveness by a telephone call to Jeremy Cleveland at 650.687.4173 or Malory Thelen at 214.969.4826 of Jones Day, and that such effectiveness also be confirmed in writing.

Very
truly yours,
FibroBiologics,
Inc.

Show Raw Text

CORRESP
1
filename1.htm

FIBROBIOLOGICS,
INC.

455
E. Medical Center Blvd.

Suite
300

Houston,
Texas 77598

February
6, 2025

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, N.E.

Washington,
D.C. 20549

    Attention:
    Joshua
    Gorsky

    RE:
    FibroBiologics,
    Inc. (the “Company”)

    Registration
    Statement on Form S-3

    File
    No. 333- 284663

Dear
Mr. Gorsky:

Pursuant
to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the
Company’s Registration Statement on Form S-3 (File No. 333-284663) be accelerated by the Securities and Exchange Commission to
4:00 p.m. Washington D.C. time on February 10, 2025, or as soon as practicable thereafter, unless the Company notifies you otherwise
prior to such time.

We
request that we be notified of such effectiveness by a telephone call to Jeremy Cleveland at 650.687.4173 or Malory Thelen at 214.969.4826
of Jones Day, and that such effectiveness also be confirmed in writing.

    Very
    truly yours,

    FibroBiologics,
    Inc.

    By:
    /s/
    Ruben A. Garcia

    Name:

    Ruben
    A. Garcia

    Title:

    General
    Counsel

SecProbe.io